Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-07

Study Completion Date

2019-09-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Short peripheral intravenous catheters (PVC) are the most frequently used invasive medical devices in hospitals. Unfortunately, PVCs often fail before the end of treatment due to the occurrence of complications, which can be mechanical, vascular or infectious. Complications lead to infusion failure and device replacement, which results in interrupted therapy, pain associated with resiting and increased health care costs for resources and staff time. Catheter related bloodstream infections (CR-BSIs) prolong hospitalization and increase treatment costs and mortality.

Prevention of these complications is based on the respect of hygiene rules and the use of bio-compatible catheters. The choice of the antiseptic solution for skin disinfection is key. Similarly, the use of new technologies such as catheters designed to minimize blood exposure, zero-reflux needleless-connectors, disinfecting caps, and flushing PVCs before and after each medication administration to maintain catheter patency are of theoretical interest, but little scientific data support their use in routine.

The primary objectives of this study are, first, to demonstrate that skin preparation with 2% chlorhexidine (CHG)-70% isopropanol decreases the risk of PVC colonization compared to skin preparation with 5% povidone iodine (PVI)-69% ethanol. Second, to demonstrate that use of a bundle of technologies including a new PVC, zero-reflux needless-connectors, disinfecting caps, and single-use prefilled flush syringes extends the time between catheter insertion and catheter failure.

The secondary objectives are to compare between the four study group incidence of phlebitis, accidental catheter removal, infiltration, catheter occlusion, CR-BSI, local infection, all-cause bloodstream infections, catheter colonization, duration of catheter remaining in place without complication, length of hospital stay, safety and patient satisfaction.

The CLEAN 3 study is an open-label, single centre, investigator-initiated, randomised, four-parallel group, two-by-two factorial trial. Patients requiring PVC for an expected 48 h will be randomised in one of four groups according to skin disinfection method and type of devices used. Randomization will be carried out through a secure web-based randomization system. Inclusions are expected to begin in January 2019 and continue until July 2019, once the number of catheters required has been reached.

Patients will be enrolled at the Emergency department of the Poitiers University Hospital before being hospitalised in one of five wards (neurology, neurology, pneumology, internal medicine and downstream emergency unit).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Alcoholic Chlorhexidine Compared to Povidone Iodine to Limit Perineural Catheter Colonisation

NCT02950246

Infection of Catheter Exit Site Catheter Related Infection

UNKNOWN NA

Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery

NCT03560193

Cardiac Surgery in Adult Patient

COMPLETED PHASE4

Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter Infection

NCT00259350

ICU Patients Requiring a Central Venous Access

COMPLETED PHASE4

Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs)

NCT05741866

Vascular Access Complication Device Related Infection Device Related Sepsis +9 more

UNKNOWN NA

Estimation of the Incidence of Colonization of Peripheral Venous Catheters After Skin Disinfection With 0.5% Sodium Hypochlorite, Preceded or Not by an Application of 70% Ethanol

NCT04391660

Skin Disinfection Before Peripheral Venous Catheter Insertion

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intravascular-catheter Colonization Catheter Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PVI et Insyte

Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD

Group Type ACTIVE_COMPARATOR

Povidone-Iodine-Alcohol

Intervention Type DRUG

Povidone-Iodine-Alcohol will be used to disinfect the skin

Insyte Autoguard BC Winged

Intervention Type DEVICE

Pose of Insyte Autoguard BC Winged

CHG et Insyte

Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD

Group Type EXPERIMENTAL

Chlorhexidine-Alcohol

Intervention Type DRUG

Chlorhexidine-Alcohol will be used to disinfect the skin

Insyte Autoguard BC Winged

Intervention Type DEVICE

Pose of Insyte Autoguard BC Winged

PVI et Nexiva

Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD

Group Type EXPERIMENTAL

Povidone-Iodine-Alcohol

Intervention Type DRUG

Povidone-Iodine-Alcohol will be used to disinfect the skin

Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes

Intervention Type DEVICE

Pose of Nexiva single port catheter

CHG et Nexiva

Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD

Group Type EXPERIMENTAL

Chlorhexidine-Alcohol

Intervention Type DRUG

Chlorhexidine-Alcohol will be used to disinfect the skin

Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes

Intervention Type DEVICE

Pose of Nexiva single port catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Povidone-Iodine-Alcohol

Povidone-Iodine-Alcohol will be used to disinfect the skin

Intervention Type DRUG

Chlorhexidine-Alcohol

Chlorhexidine-Alcohol will be used to disinfect the skin

Intervention Type DRUG

Insyte Autoguard BC Winged

Pose of Insyte Autoguard BC Winged

Intervention Type DEVICE

Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes

Pose of Nexiva single port catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (age ≥ 18 years) patients,
* Having clinical indication for placement of a single PVC for at least 48 hours (no minimum port access during the study duration),
* Willing and able to provide informed consent.

Exclusion Criteria

* Known allergies to CHG, PVI, isopropanol or ethanol,
* Participation to another clinical trial aimed at reducing PVC complications,
* Suspicion of bloodstream infection at catheter insertion,
* Skin injury a catheter insertion site increasing the risk of catheter infection,
* PVC inserted extremely urgently, making it impossible to comply with the protocol,
* Intravascular catheter in place within the last 2 days, or within the last 2 weeks and with local signs of catheter complication,
* Difficult catheter insertion suspected (obesity, known IV drug users, non-visible venous network after placement of a tourniquet...),
* Patients already enrolled in this study,
* Terminal or moribund patient not expected to live more than one week,
* Patients not benefiting from a Social Security scheme or not benefiting from it through a third party,
* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
* Pregnant or breastfeeding women
* Women at age to procreate and not using effective contraception

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No